ARAY Accuray Inc.: Market Capitalization to Book Value Ratio

Accuray Inc. (ARAY) - corporate logo

Accuray Incorporated (ARAY) develops high-tech robotic systems capable of tracking tumor movement in real time to ensure the most gentle impact on tissues. The company occupies a stable niche by focusing on equipment upgrades and unique precision, which allows it to avoid price wars. This price chart reflects the dynamics of a business that supplies CyberKnife and TomoTherapy systems to hospitals, with the current indicator standing at 0.34.

Accuray Incorporated (ARAY) - Market Capitalization to Book Value Ratio from 07/04/2022 to 10/27/2026
Finished products of Accuray Inc

For Accuray Incorporated, which maintains its niche through precision robotic systems, this indicator reflects the extent of the market's revaluation of its unique technological assets. By analyzing the dynamics of the market value to book value ratio, an investor compares the current exchange value with net equity, which allows for the determination of a margin of safety and helps avoid purchasing the asset at the peak of unjustified optimism.

Main competitors

Market Cap to Net Assets Ratio ONC|halozyme.com (HALO) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio RVMD|Market Cap to Net Assets Ratio Ascentage Pharma Group International|Market Capitalization to Book Value Ratio CGON|Market Capitalization to Book Value Ratio URGN (UroGen Pharma Corp)|BCAX - Market Value to Book Value Ratio|Capitalization to Book Value Ratio personalis.com PSNL|ERAS: Market Capitalization to Book Value Ratio|DCTH - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio YMAB|AURA (Aura Corp) - Market-to-Book Ratio|CADL - Market Value to Book Value Ratio|Market Value to Book Value SELLAS Life Sciences Group Inc. (SLS)|Actuate Therapeutics (ACTU) - Market Cap to Net Assets Ratio|Market Value to Book Value Citius Oncology Inc. (CTOR)|TuHURA Biosciences - Market Capitalization to Book Value Ratio|TARA - Market Cap to Net Assets Ratio|Fate Therapeutics, Inc. - Market Cap to Net Assets Ratio|WHWK: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio tscan.com TCRX|Champions Oncology, Inc. (CSBR) - Market Value to Book Value|Market Capitalization to Book Value Ratio XBIT (XBiotech Inc)|Market-to-Book Ratio CEL-SCI Corp|Market Capitalization to Book Value Ratio OSTX|Market Capitalization to Book Value Ratio Radiopharm Theranostics Ltd (RADX)|Artiva Biotherapeutics - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Adlai Nortye Ltd ANL|VERU: Market Capitalization to Book Value Ratio|Tempest Therapeutics Corp (TPST) - Market Cap to Net Assets Ratio|XLO: Market Cap to Net Assets Ratio|RENB (Renovaro) - Market Capitalization to Book Value Ratio|MURA - Market Value to Book Value Ratio|Market Value to Book Value Kairos Pharma Inc|Market Capitalization to Book Value Ratio OKUR|Market Capitalization to Book Value Ratio w2.cytomed.sg GDTC|CRIS: Market Cap to Net Assets Ratio|APLM - Market-to-Book Ratio|Market Cap to Net Assets Ratio Tharimmune (THAR)|ADVB - Market Value to Book Value|Genprex, Inc - Market Capitalization to Book Value Ratio|CLDI (Calidi Biotherapeutics, Inc.) - Market Capitalization to Book Value|Market Value to Book Value Ratio Sunshine Biopharma (SBFM)|Capitalization to Book Value Ratio Xenetic Bio|Market Capitalization to Book Value Ratio SLRX (Salarius Pharmaceuticals, Inc.)|Market Cap to Net Assets Ratio PPBT (Purple Biotech Ltd)|AONC: Market Value to Book Value Ratio|BeiGene Ltd - Market-to-Book Ratio|Market Value to Book Value Ratio Checkpoint Therapeutics (CKPT)|ELEV: Market Value to Book Value|Market Value to Book Value Ratio icadmed.com (ICAD)|IKNA (Ikena Oncology) - Market Capitalization to Net Assets|Market Value to Book Value Ratio NTBL (Notable Labs Inc.)|Market-to-Book Ratio VIRX|MorphoSys AG (MOR) - Market Value to Book Value Ratio|Market Value to Book Value nayabiosciences.com (NAYA)|Market Capitalization to Book Value Ratio AAPGV (Ascentage Pharma)